(HealthDay News) – Recommendations for treatment of systemic juvenile idiopathic arthritis (JIA), including those cases with or without active systemic features, have been updated to reflect an extensive literature review and evaluation of more than 1,000 scenarios, according to a special article published in the October issue of Arthritis & Rheumatism.
Sarah Ringold, MD, from Seattle Children’s Hospital, and colleagues conducted a systematic review of the literature and evaluation of 1,226 scenarios to develop recommendations using the RAND/UCLA Appropriateness Method. The 2013 recommendations update the 2011 recommendations.
The authors discuss recommended initial therapeutic options, as well as therapeutic options for continued disease activity after initial therapy, including the use of canakinumab and tocilizumab, which have been added to the 2013 recommendations. Treatment recommendations are included for systemic JIA with active systemic features and without active systemic features, and with varying degrees of synovitis.
“These recommendations, representing the culmination of a rigorous systematic literature review and the use of the RAND/UCLA appropriateness methodology, are an important contribution to the care of children with systemic JIA, offering recommendations to providers caring for children with this challenging disease,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.